Skip To Main Content
Macé M. Schuurmans on Muck Rack

Macé M. Schuurmans

As seen in: PLOS ONE, MDPI, Annals of Internal Medicine, Swiss Medical Weekly
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Macé M.

Contact Macé M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function

|
By Annette Audigé, Alain Amstutz, Macé M. Schuurmans, Patrizia Amico
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Audigé A, Amstutz A, Schuurmans MM, Amico P, Braun DL, Stoeckle MP, et al. (2025) Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function. PLoS ONE 20(1): e0317965.
Open in Who Shared Issue with article?

Medicina | Free Full-Text | Multimodal Remote Home Monitoring of Lung Transplant Recipients during COVID-19 Vaccinations: Usability Pilot Study of the COVIDA Desk Incorporating Wearable Devices

|
By Macé M. Schuurmans, Xiang Li, Lukas U. Zimmerli, Michal Muszynski
| MDPI
2.3. Study Materials The COVIDA desk (Figure 2) is a novel, custom-built disease home monitoring system. It combines multiple sensors in a compact format with a single power plug for device charging. All components of the COVIDA desk are Conformité Européenne (CE)-certified.
Open in Who Shared Issue with article?

Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol

|
By Macé M. Schuurmans, Miro E. Raeber, Maurice Roeder, René Hage
| MDPI
Abstract : Achieving adequate immunosuppression for lung transplant recipients in the first year after lung transplantation is a key challenge. Prophylaxis of allograft rejection must be balanced with the adverse events associated with immunosuppressive drugs, for example infection, renal failure, and diabetes.
Open in Who Shared Issue with article?
See all 6 articles